Joshua Reed compensation by year
Aldeyra Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Salary | $377,000 | $382,143 | $432,143 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $238,578 | $520,532 | $0 |
| Option awards | $1,359,210 | $621,962 | $1,231,734 |
| Non-equity incentive | $140,244 | $152,857 | $172,857 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $66,243 | $11,400 | $11,400 |
| Total | $2,181,275 | $1,688,894 | $1,848,134 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aldeyra Therapeutics, Inc. DEF 14A filed April 25, 2022, accession 0001193125-22-117585, and prior-year filings.
How this page was built: the Aldeyra Therapeutics, Inc. filed document, accession 0001193125-22-117585. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 103,281 | $413,124 | — |
| RSU | 14,819 | $59,276 | — |
| Option | 130,209 | — | $3.78 |
| Option | 115,768 | — | $11.71 |
| Option | 10,952 | — | $6.80 |
| Option | 67,709 | — | $8.05 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Aldeyra Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Aldeyra Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Todd Brady | President and Chief Executive Officer | $3,455,670 |
| Joshua Reed · this page | Chief Financial Officer | $1,848,134 |
| Stephen Machatha | Chief Development Officer | $1,431,416 |
The full Aldeyra Therapeutics compensation record
free company briefThis page is one person within Aldeyra Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aldeyra Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.